Trade Jazz Pharmaceuticals plc - JAZZ CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.89 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024151% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001929% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 124.23 |
| Open | 122.21 |
| 1-Year Change | -1.93% |
| Day's Range | 120.49 - 122.63 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | 121.25 | -0.83 | -0.68% | 122.08 | 122.63 | 120.14 |
| Nov 14, 2024 | 124.23 | -1.26 | -1.00% | 125.49 | 126.11 | 123.45 |
| Nov 13, 2024 | 127.43 | 0.30 | 0.24% | 127.13 | 128.79 | 126.21 |
| Nov 12, 2024 | 127.58 | 1.53 | 1.21% | 126.05 | 128.15 | 125.00 |
| Nov 11, 2024 | 126.66 | 2.09 | 1.68% | 124.57 | 127.22 | 122.50 |
| Nov 8, 2024 | 123.17 | 5.23 | 4.43% | 117.94 | 123.85 | 117.55 |
| Nov 7, 2024 | 118.26 | 2.98 | 2.59% | 115.28 | 121.20 | 114.82 |
| Nov 6, 2024 | 111.23 | -0.02 | -0.02% | 111.25 | 113.46 | 110.40 |
| Nov 5, 2024 | 111.01 | 2.70 | 2.49% | 108.31 | 111.56 | 107.73 |
| Nov 4, 2024 | 109.30 | 0.20 | 0.18% | 109.10 | 111.09 | 109.10 |
| Nov 1, 2024 | 110.27 | 0.23 | 0.21% | 110.04 | 110.87 | 109.64 |
| Oct 31, 2024 | 109.83 | -0.12 | -0.11% | 109.95 | 111.46 | 108.31 |
| Oct 30, 2024 | 112.77 | 2.78 | 2.53% | 109.99 | 113.39 | 109.49 |
| Oct 29, 2024 | 111.38 | 0.88 | 0.80% | 110.50 | 111.95 | 110.10 |
| Oct 28, 2024 | 111.26 | 1.45 | 1.32% | 109.81 | 112.47 | 108.86 |
| Oct 25, 2024 | 109.46 | 1.69 | 1.57% | 107.77 | 110.43 | 107.77 |
| Oct 24, 2024 | 107.94 | -2.96 | -2.67% | 110.90 | 111.23 | 107.30 |
| Oct 23, 2024 | 110.95 | -0.96 | -0.86% | 111.91 | 113.03 | 110.55 |
| Oct 22, 2024 | 112.98 | 0.87 | 0.78% | 112.11 | 113.67 | 112.08 |
| Oct 21, 2024 | 113.02 | -1.30 | -1.14% | 114.32 | 114.97 | 112.67 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Jazz Pharma Company profile
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Jazz Pharmaceuticals PLC revenues increased 31% to $3.09B. Net loss totaled $329.7M vs. income of $238.6M. Revenues reflect Sunosi segment increase from $28.3M to $2.34B, Zepzelca segment increase from $90.4M to $246.8M, United States segment increase of 32% to $2.82B, Europe segment increase of 31% to $230.2M. Net loss reflects Selling.
Equity composition
Common Stock $.0001 Par, 4/11, 150M auth., 40,741,809 issd. Insiders & stakeholders own 2.30%. IPO 6/1/07, 6M shares @ $18 per share by Morgan Stanley & Co. Incorporated, Lehman Brothers Inc. 5/07 Reverse stock split 1 for 11.06701. PO: 7/08, 3.8M shares.
| Industry: | Pharmaceuticals (NEC) |
Fifth Fl
Waterloo Exchange
DUBLIN
DUBLIN 4
IE
News
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com